ribociclib,naporafenib,rineterkib,trametinib
novartis
['melanoma', 'lxh254', 'novartis']
at the 2022, present the phase ii study of multiple lxh254 drug combinations in patients (pts) with unresectable/metastatic, braf v600- or nras-mutant melanoma. explore more: #esmo2022 #esmo #esmo22 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry